PBYI vs. RAPT, AKBA, MRNS, URGN, ANAB, MLYS, SAGE, ZYME, GHRS, and HROW
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include RAPT Therapeutics (RAPT), Akebia Therapeutics (AKBA), Marinus Pharmaceuticals (MRNS), UroGen Pharma (URGN), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Sage Therapeutics (SAGE), Zymeworks (ZYME), GH Research (GHRS), and Harrow (HROW). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Puma Biotechnology has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Puma Biotechnology had 4 more articles in the media than RAPT Therapeutics. MarketBeat recorded 4 mentions for Puma Biotechnology and 0 mentions for RAPT Therapeutics. Puma Biotechnology's average media sentiment score of 0.12 beat RAPT Therapeutics' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the media.
Puma Biotechnology received 450 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 66.58% of users gave Puma Biotechnology an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
Puma Biotechnology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Puma Biotechnology presently has a consensus target price of $7.00, indicating a potential upside of 98.58%. RAPT Therapeutics has a consensus target price of $24.67, indicating a potential upside of 542.36%. Given RAPT Therapeutics' higher possible upside, analysts clearly believe RAPT Therapeutics is more favorable than Puma Biotechnology.
Puma Biotechnology has a net margin of 6.79% compared to RAPT Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 35.49% beat RAPT Therapeutics' return on equity.
Summary
Puma Biotechnology beats RAPT Therapeutics on 14 of the 18 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
